RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Henlius Biotech’s biosimilar to Roche’s Rituxan has been approved by China’s NMPA, the first biosimilar approved in China. Shanghai Henlius, which was set up in 2010 as a JV between Shanghai Fosun Pharma and US-based Henlius, focuses on novel and biosimilar mAbs. In a China Phase III trial, the Henlius biosimilar showed it matched the efficacy of the Roche original in patients with CD20-positive non-Hodgkin lymphoma. Ironically, Rituxan was the first monoclonal antibody approved for US use as a cancer treatment.
Source: China Biotoday
